Anti-NR10 antibody and use thereof
The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.
1. An isolated anti-NR10 antibody selected from the group consisting of:
(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 206 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 207 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 208 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 209 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 210 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 211 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 212 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(8) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 213 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(9) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 214 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(10) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 215 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220;
(11) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 221; and
(12) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 217 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 221.
2. A pharmaceutical composition comprising the antibody of claim 1 .
3. An isolated anti-NR10 antibody selected from the group consisting of:
(1) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 224 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(2) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(3) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 226 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(4) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 227 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(5) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 228 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(6) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 229 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(7) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 230 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(8) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 231 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(9) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 232 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(10) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 233 and a light chain comprising the amino acid sequence of SEQ ID NO: 238;
(11) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 234 and a light chain comprising the amino acid sequence of SEQ ID NO: 239; and
(12) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 235 and a light chain comprising the amino acid sequence of SEQ ID NO: 239.
4. A pharmaceutical composition comprising the antibody of claim 3 .
5. A method of treating atopic dermatitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2 .
6. A method of treating atopic dermatitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 4 .
7. A method of treating chronic dermatitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2 .
8. A method of treating chronic dermatitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 4 .
9. A method of treating rheumatism in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2 .
10. A method of treating rheumatism in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 4 .
11. A method of treating osteoarthritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2 .
12. A method of treating osteoarthritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 4 .
13. A method of treating rheumatoid arthritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2 .
14. A method of treating rheumatoid arthritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 4 .